In December 2025, Halozyme Therapeutics announced a global collaboration and exclusive license agreement granting Takeda ...

Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...

The crushing January pressure to Get In Shape has inspired millions of Britons to fill their shopping trolleys with a ...

Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda.

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...

Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive ...

A toothbrush that detects diabetes, a robot that folds laundry and a watch that spots dementia. "What'll they think of next?" ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are ...

Halozyme Therapeutics (HALO) shares are in focus after the company entered a non exclusive global collaboration with Skye ...

Administered in a 30-45 minute session, the Fraxel treatment makes “deep columns” in your skin called “micro-thermal zones,” ...

Our shared vision is simple: sophisticated care and increased access. By integrating access, data, and clinical pathways, we will improve outcomes and the overall experience across all levels of care.

Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.